MedTrace Logo

Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype

NCT02950441 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-06-07

No results posted yet for this study

Summary

This study is designed to assess the physiological consequences of elevating Nicotinamide Adenine Dinucleotide (NAD+) availability using Nicotinamide Riboside (NR) supplementation in skeletal muscle tissue, and examine its effect upon muscle metabolic phenotype.

Conditions

  • Aging

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside

OTHER

Placebo

Sponsors & Collaborators

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Gareth Lavery, PhD · Institute of Metabolism and Systems Research, University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
70 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2018-09-30
Completion
2019-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02950441 on ClinicalTrials.gov